Drug Profile
AUR 109
Alternative Names: AUR-109; ODM 203Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Orion
- Developer Aurigene Oncology; Orion
- Class Antifibrotics; Antineoplastics
- Mechanism of Action Fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Fibrosis; Hepatic fibrosis; Solid tumours
Most Recent Events
- 14 Apr 2023 Pharmacodynamics data from a preclinical study in Solid tumors presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 04 Jan 2023 Phase-II clinical trials in Fibrosis in India (PO), prior to January 2023 (Aurigene pipeline, January 2023)
- 04 Jan 2023 Phase-II clinical trials in Hepatic fibrosis in India (PO), prior to January 2023 (Aurigene pipeline, January 2023